Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netupitant-palonosetron vs ondansetron for prevention of opioid-induced nausea and vomiting in lung cancer pain
ChiCTR2500108969Phase 4Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of netupitant + palonosetron and ondansetron in bronchial carcinoma and Opioid-induced nausea and vomiting (OINV) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Incidence of opioid-induced nausea and vomiting (OINV) during opioid therapy at Day 14. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
netupitant + palonosetronondansetron
03
Conditions
bronchial carcinomaOpioid-induced nausea and vomiting (OINV)
Beyond the preview
Go deeper on ChiCTR2500108969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108969.